Aktiesnakken — Februar 2012

[Jesrose]

Ja lad os håbe det Rune

[troldmanden]

jeg tror ik vi kommer til at se nogen ptc forlængelse i år.......

[Revilo]

Fint regnskab fra A&O Johansen

[RuneBJensen]

Trold you got mail.

[Kristensen]

Revilo tjek seneste debat tråd om AO

[troldmanden]

and you got answer

[actdk]

Tror det var shortluk hos BRC.

[actdk]

DDB kørte den ret hurtigt op i 57 - og de smed en del da den rundede 60.

[actdk]

blot en observation..

[RuneBJensen]

håber ikke at det går lige så hurtigt ned igen.. selvom det næsten ser sådan ud.

[troldmanden]

et høre da lidt mere til sjældenhederne at vi ser SÅ store bevægelser indfor så kort tid i en C20

[troldmanden]

og vel at mærke uden nyheder

[actdk]

Pandora og VWS af og til.

[troldmanden]

og med en oms der indenfor under 60 min har fordoblet hele dagens oms

[troldmanden]

pandora er ik c20

[troldmanden]

exiqon ude

[troldmanden]

Revenue increased 19% to DKK 111.5 million (DKK 93.5 million): •Organic growth in Life Sciences’ product sales was 36%.
•Life Sciences’ product sales growth is primarily driven by Exqon’s proprietary miRCURY LNA Universal RT PCR platform for academic and clinical microRNA research.

[troldmanden]

Gross profit increased 29% to DKK 62.2 million (DKK 48.1 million):•Exiqon Life Sciences’ gross margin was realized at 51.4% compared to 46.6% in 2010 driven by higher volumes in product sales and lower services revenue in line with strategy.
•Total operating costs decreased 13% to DKK 76.4 million (DKK 88.3 million) excluding special items

[actdk]

Nej også rigtigt...

[troldmanden]

Expectations for 2012: •Following a positive EBITDA in the fourth quarter of 2011 and having achieved its full year guidance for 2011, Exiqon is now on the way to profitability.
•In 2012, Exiqon expects a positive EBIT and positive cash flow from operating activities driven by continued strong growth in research product sales of around 25% (excluding OEM).
•Total revenue is expected around DKK 130 million.